Maryland, United States – GlaxoSmithKline gets a warning from the United States regarding the conditions of their facilities in Ste-Foy, Que.
To maintain its reputation internationals, the drug maker should follow the warning. They are currently the largest flu vaccine provider in Canada. They cannot afford to lose all they have done in a very basic sanitary issue like this one. In a letter dated June 24, it said that the company deviated from the good works that they been doing.
They are already expected to deliver quality manufacturing. Being the big company that they are, there should be no questions regarding their ability to provide urgent care in their manufacturing facilities.
The Problems and the Consequences
Currently, GlaxoSmithKline is producing several products for the consumption of the United States. However, without any quick recovery from their problems in the facility, the country will be forced to eliminate it from the list. The administration is expecting them to submit changes any time soon.
The main problem lies on the microbial contamination in their facility. Urgent care clinics will tell you that these are very common in such places. This could affect the quality of the drugs that they are producing if they are not handled properly. This is the main reason why the United States would like to see results from the drug company promptly.
The Drug Company Is Already Working On It
This warning is also good for the company because their mistakes are corrected. The GlaxoSmithKline officials say that they are working with agencies to correct whatever needs to be corrected.
They say that they are very committed in making sure that these warnings do not go to waste. Plus, they are already working with some agencies for the issue to be settled.
They added that there are series of quality reviews done before vaccines even reach an urgent care clinic. Anything that will not pass the process will be discarded right away. Their seasonal flu vaccines, which they are known for, are not affected by these manufacturing problems. They also have enough supply in case urgent care near me needs more of their products.
GlaxoSmithKline is already an institution when it comes to providing vaccines to the rest of the world. They will not risk all the hard work in a manufacturing as small as this. However, the move from the United States is a class act. They should still worry about these matters even with bigger companies. The question is, when will they be cleared? Will this happen again?
